KRAS G12C MUTATION
Clinical trials for KRAS G12C MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C MUTATION trials appear
Sign up with your email to follow new studies for KRAS G12C MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called KQB365 in adults with advanced solid tumors (like colorectal cancer) that have specific KRAS mutations (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors when given alone or with other cancer…
Matched conditions: KRAS G12C MUTATION
Phase: PHASE1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New triple therapy targets hard-to-treat lung cancer before surgery
Disease control Recruiting nowThis study tests a new approach for people with a certain genetic lung cancer (KRAS G12C mutation) that can be removed with surgery. Before surgery, patients receive a targeted pill (fulzerasib) for 6 weeks, then a 2-week break, followed by 3 cycles of immunotherapy (sintilimab) …
Matched conditions: KRAS G12C MUTATION
Phase: PHASE2 • Sponsor: Jianxing He • Aim: Disease control
Last updated May 11, 2026 20:51 UTC